The synthetic and docking studies of Chromonyl linked thiazolidenedione (TZD), rhoadanine (RH), diethyl malonate (DEM), methyl acetoacetate (MAA), barbituric acid (BA) and thiobarbituric acid (TBA) analogues in an effort to develop novel peroxisome proliferator activated receptors ligands expected to exhibit PPARγ partial agonism in the management of hyperglycemia and hyperlipidemia for the treatment of type 2 diabetes is reported. Docking studies showed expected results.